Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: LGND stock price vs A: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at A's multiple
Needs A P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · A FY 2025 (ended Oct 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Bear
$101.45
Base
$119.35
Bull
$137.25
AGILENT TECHNOLOGIES, INC. · implied price per share
Bear
$41.87
Base
$49.26
Bull
$56.65
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.25x
0.50x
Net debt / EBITDA
Leverage against operating earnings
-2.31x
0.79x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$1.82B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
THERMO FISHER SCIENTIFIC INC.
LGND vs TMO
ILLUMINA, INC.
LGND vs ILMN
BIO-TECHNE Corp
LGND vs TECH
BRUKER CORP
LGND vs BRKR
Azenta, Inc.
LGND vs AZTA
WATERS CORP /DE/
LGND vs WAT
$252.03M
$3.35B
Live quote
Edwyn research
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
